We have shown that it is possible to produce a satisfactory clinical response with a low UV-A dosage regime in approximately one-third of patients with widespread chronic psoriasis. UV-B phototherapy is as effective initially, but the improvement is not as well maintained as that resulting from photochemotherapy (PUVA). However, in view of the probability that unwanted side effects of PUVA are related to the amount of UV-A irradiation administered, it would seem appropriate to restrict the use of the higher dosage regimes to selected patients and to those who have not responded to an initial low dosage regime or to UV-B phototherapy.
No takes yet. Share an insight, caveat, or question.
Kenicer et al. (1981) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: